F2 and central nervous system cancer: FDA-approved drugs do not seem to act on ‘LXR/RXR Activation’, ‘Extrinsic Prothrombin Activation’; ‘Ethanol Degradation IV’, ‘Fatty Acid oxidation’ and ‘Glioma Invasiveness Signaling’.